Do biotechs ever go on sale? Or are they always telling you somethingce I struggle with that question. I follow the science and as long as the trials are going the right way I hang in despite some nasty slides. case in point IOVA. I probably own at $17. It'sdown in Fla with Big Pete... It's freakn' $12. I STILL BELIEVE Iovance Biotherapeutics, Inc. IOVA incurred a loss of 63 cents per share in second-quarter 2022, wider than the Zacks Consensus Estimate of a loss of 60 cents and the year-ago quarter’s loss of 53 cents. Without any marketed product and revenue-generating collaboration, the company did not record any revenues during the quarter. Shares of Iovance have declined 34.3% so far this year compared with the industry’s 19.7% fall. Zacks Investment Research Quarter in Detail Research & development expenses were $73.4 million, 18.2% higher than the year-ago quarter, primarily due to increased related personnel costs and facility building costs. General and administrative expenses increased 36.4% from the prior-year quarter to $26.3 million due to an increase in related personnel costs and facility-related costs. The company had $430.9 million in cash, cash equivalents, short-term investments and restricted cash as of Jun 30, 2022, compared with $516.0 million on Mar 31, 2022. It expects the cash level to be sufficient to fund the current and planned operations in 2024. Pipeline Updates Iovance is developing its lead pipeline candidate, lifileucel, as a monotherapy for treating metastatic melanoma and metastatic cervical cancer in separate pivotal phase II studies — C-144-01 and C-145-04 — for metastatic melanoma and recurrent, metastatic or persistent cervical cancer, respectively, in previously-treated patients. This April, the FDA provided positive feedback regarding the potency assays and assay matrix for lifileucel, concerning the treatment of melanoma. The regulatory body had previously raised concerns over the potency assays in 2020. The resolution of the potency assay-related concern was necessary prior to the submission of a biologics license application (BLA) for lifileucel. Earlier in May, Iovance announced data from pivotal Cohort 4 of the C-144-01 study, which evaluated lifileucel in heavily pre-treated melanoma patients. Data from the study showed that patients who were treated with the therapy achieved an objective response rate (ORR) of 29%. This data was consistent with the Cohort 2 of the study, which achieved an ORR of 35%. IOVA plans to use this data to support the above BLA filing. NOT GREAT BUT DECENT Following the successful pre-BLA meeting with the FDA held last month, Iovance will start a rolling BLA submission for lifileucel in melanoma later this month which is expected to be completed in fourth-quarter 2022. Iovance has also been engaged in discussions with the FDA for lifileucel in cervical cancer. Based on these discussions, IOVA plans to reopen enrolment in Cohort 2 of the C-145-04 study. The study will enroll patients who have previously received an anti-PD-1 therapy. IOVA expects this study to support a potential BLA filing for lifileucel in cervical cancer indication. This part excites me to no end- combined with Keytruda amazing things happen. Iovance plans to start a separate phase III study to evaluate the combination regimen of lifliecel and Merck’s MRK Keytruda (pembrolizumab) in frontline metastatic melanoma in late 2022. The combination of lifileucel and Meck’s Keytruda, which has already been evaluated in Cohort 1A of the multi-cohort phase II study (IOV-COM-202), has demonstrated an overall response rate of 67% in the given indication. This late-stage study will also serve as a confirmatory study for the pivotal Cohort 4 of the C-144-01 study.
OMG... I told you this one was a dog at $24 when you were telling everyone to buy it. It's $16 now. Dead money. Hear what I say.... Sell Six right now for $20.72 and buy TOST. Sorry, I can't control what time I get my alerts, it has a lot to do with order flow. The market's still open Stoney... quit being a rookie and trade. What is this "no after hours stuff"? You'll never get successful Stoney passing up golden opportunities. Why don't you pick 5 stocks right now and I'll give you 5 straight from the scanner. Lets write them down. Is this easy enough for you since you are obviously backing out of the portfolio challenge. It should be an easy win for you right?
TOST is $20.20 Isn't that perfect vision? You don't want a $20 stock that will take out $23 tomorrow?
Here are two lads with fabulous voices. I used these guys a lot when I was a DJ THIS IS RADIO SAVANT-!
Canadian energy firms posting massive profits especially ones in Nat Gas. I currently hold the following : Athabaska, Gear Energy, Baytex, Pipestone, Birchcliff ( n. gas ), Crew Energy ( n. gas ). Recent trades in Crescent Point, Enerplus, Cenovus, WhiteCap; sold to get a little better action in others on news but all are decent buy candidates on dips. With Nat Gas rally I'm considering NuVista again as a trade, rebought Crew as a trade earlier in the week, bought Birchcliff as an earnings play and they posted a huge number. Crew was on sale at 0.14 a share in 2020 is now roughly $6 and posted a quarterly net income of 0.55. Gives one an idea of the dynamic in play. Pipestone super cheap after getting hammered in recent weeks was under $4 posted 0.29 net income on the quarter. Gear tripled their dividend last week to 10% yield it's gradually repricing towards at least $2 imo. Canadian investors are notoriously conservative and are basically pricing in $50-60 WTI in a recession. As the cash rolls in on these firms, the value story is compelling and hard to ignore.
New listings of U.S. homes fell the most since the depths of the Covid-19 pandemic in 2020 as sellers respond to deteriorating buying demand amid higher mortgage rates. Specifically, new listings dipped 12% from a year ago during the fourweeks ended August 7, the sharpest decline since June 2020, according to real estate brokerage Redfin'sdata, which covers over 400 U.S. metro areas. On a similar note, pending home sales, which tracks home sales in which a contract has been signed but the sale hasn't yet closed, slid 16% Y/Y. Some homeowners appear to be hesitant to buy a new home since they would likely have to pay a much larger mortgage rate than they do now. For the week ended August 11, the30-year fixed-rate mortgage jumped to an average of 5.22% from just 2.87% a year before. At the same time, though, homebuyers seem to be pulling back as well amid an increase in the supply of homes. The total number of homes for sale is up 4% Y/Y, suggesting the housing shortage is starting to ease, Redfin said. “Buyers are backing off due to rising housing costs and sellers are holding back because they realize they won't get the bidding war they would have gotten six months ago,” said Redfin Deputy Chief Economist Taylor Marr. “The good news is this is bringing balance to the market. If mortgage rates resume their downward trajectory, more buyers and sellers could get back in the game.”
BECAUSE THE COMPANY HAS $411 MILLION DOLLARS OF DEBT, A MARKET-CAP OF $780M, GROSS MARGINS OF -33%, AND THEY LOST -$6.50/SHARE LAST YEAR IN EARNINGS. Revenue doubled. Bfd.... it needs to go up by a factor of 10. The company trades at 100X enterprise to ebitda. Sure it'll get a little pop on the headline tomorrow, but this thing will be below $15 before ya know it. Buy TOST
I have found some very good action in the oil services field. In particular I like HLX--They used to be Cal Dive which I owned years ago. Description Helix Energy Solutions Group, Inc., an offshore energy services company, provides specialty services to the offshore energy industry primarily in Brazil, the Gulf of Mexico, North Sea, the Asia Pacific, and West Africa regions. The company operates through three segments: Well Intervention, Robotics, and Production Facilities. It engages in the installation of flowlines, control umbilicals, and manifold assemblies and risers; trenching and burial of pipelines; installation and tie-in of riser and manifold assembly; commissioning, testing, and inspection activities; and provision of cable and umbilical lay, and connection services. The company also provides well intervention, intervention engineering, and production enhancement services; inspection, repair, and maintenance of production structures, trees, jumpers, risers, pipelines, and subsea equipment; and related support services. In addition, it offers reclamation and remediation services; well plug and abandonment services; pipeline abandonment services; and site inspections. Additionally, the company offers oil and natural gas processing facilities and services; and fast response system, as well as site clearance and subsea support services. It serves independent oil and gas producers and suppliers, pipeline transmission companies, renewable energy companies, and offshore engineering and construction firms. The company was formerly known as Cal Dive International, Inc. and changed its name to Helix Energy Solutions Group, Inc. in March 2006. Helix Energy Solutions Group, Inc. was incorporated in 1979 and is headquartered in Houston, Texas.